Evidence map›Paper›PMID 41113250›Full record

ArticleThe journal of allergy and clinical immunology. Global2025

Effectiveness of indacaterol/glycopyrronium/mometasone for refractory asthmatic cough after switching from inhaled corticosteroid/long-acting β

Akio Niimi, Hiroyuki Ohbayashi, Hitoshi Asamoto, Tadashi Kamei, Arihiro Kiyosue, Yasushi Fukushima, Hirofumi Matsuoka, Naoki Miyao, Takao Tochigi, Eiji Yamagata and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Akio NiimiDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan.
Hiroyuki OhbayashiTohno Chuo Clinic, Gifu, Japan.
Hitoshi AsamotoAsamoto Internal Medicine Clinic, Kyoto, Japan.
Tadashi KameiKamei Internal Medicine and Respiratory Clinic, Kagawa, Japan.
Arihiro KiyosueTokyo-Eki Center-Building Clinic, Tokyo, Japan.
Yasushi FukushimaFukuwa Clinic, Tokyo, Japan.
Hirofumi MatsuokaMatsuoka Solairo Clinic, Kobe, Japan.
Naoki MiyaoDepartment of Respiratory Medicine, Nippon Kokan Hospital, Kanagawa, Japan.
Takao TochigiTochigi Takao Clinic, Kagoshima, Japan.
Eiji YamagataYamagata Clinic, Oita, Japan.
Toshinaga TsujiDivision of Medical Affairs, Novartis Pharma, Tokyo, Japan.
Toshiaki MikamiDivision of Medical Affairs, Novartis Pharma, Tokyo, Japan.
Junpei SaitoDepartment of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Yoshihiro KanemitsuDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan.
Tomoko TajiriDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan.
Johsuke HaraDepartment of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cough is a major symptom in poorly or partially controlled asthma, which persists despite treatment, thus impairing quality of life. Objectives: The primary objective was to demonstrate the superiority of medium-dose indacaterol, glycopyrronium, and mometasone furoate (IND/GLY/MF) over high-dose inhaled corticosteroids (ICS)/long-acting β Methods: In this multicenter, randomized, open-label, parallel-group study, 118 patients were randomized to receive either IND/GLY/MF or high-dose ICS/LABA (fluticasone/vilanterol [FF/VI] or budesonide/formoterol [BUD/FM]) for 8 weeks. Efficacy was measured by the Japanese version of the Leicester Cough Questionnaire at week 8. Additional analyses included a visual analog scale, the 6-item Asthma Control Questionnaire, respiratory function, fractional exhaled nitric oxide, and blood eosinophil/neutrophil measurements. Registration: Public clinical trials registry as study jRCTs04122000. Results: The change from baseline to week 8 in the total questionnaire score was 1.99 ± 3.48 in the IND/GLY/MF group and 2.50 ± 4.28 in the high-dose ICS/LABA group, with no statistically significant difference between the two groups ( Conclusion: Symptoms improved comparably between medium-dose IND/GLY/MF and high-dose ICS/LABA combinations, although no superiority could be demonstrated. Medium-dose IND/GLY/MF may be an alternative to high-dose ICS/LABA.

Indexed as

Asthmacougheosinophilsfractional exhaled nitric oxide (Feno)ICS/LABAindacaterol/glycopyrronium/mometasoneneutrophils

Identifiers

PMID41113250
PMCPMC12528903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.